The efficacy of Arlevert therapy for vertigo and tinnitus.
We were interested in determining the efficacy of Arlevert therapy in vertigo and tinnitus patients, especially as it compared to the efficacy of the drug's two component agents, dimenhydrinate and cinnarizine. We conducted a comparative, randomized, double blind, multicenter, parallel group study involving a group of patients (n = 122) with vertigo and tinnitus of peripheral or central origin. The three test groups, nearly equal in size, were administered three times daily for 4 weeks one of the three agents being evaluated. To evaluate therapeutic success, we studied patients' vertigo symptoms, concomitant vegetative symptoms, CCG parameters, and electronystagmographic and audiometric parameters. We also obtained subjective assessments of outcomes from the test patients. Our results led us to conclude that Arlevert is more effective than either of its component drugs alone in treating vertigo and tinnitus. The drug also was well tolerated.
Novotný
M
M
Department of Otolaryngology, University Hospital, Brno-Bohunice, Czech Republic.
Kostrica
R
R
Círek
Z
Z
D001299:Audiometry; D002936:Cinnarizine / Q000627:therapeutic use*; D004111:Dimenhydrinate / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004584:Electronystagmography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014012:Tinnitus / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014717:Vertigo / Q000188:drug therapy* / Q000503:physiopathology; D014724:Vestibular Function Tests
D004338:Drug Combinations; C410867:cinnarizine, dimenhydrinate drug combination; D002936:Cinnarizine; D004111:Dimenhydrinate